About: CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy
Creator	Motoyama, Satoru Sato, Yusuke Akiyuki, Sasaki Jun-Ichi Ogawa, Wakita Key, Maruyama Kiyotomi, • Tomohiko, Yoshino
Source	PMC
abstract	BACKGROUND: Cytomegalovirus (CMV) infection is endemic worldwide. Although CMV reactivation often becomes a serious problem in immunocompromised patients, the prevalence of CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy has yet to be determined. METHOD: Among 175 consecutive patients with thoracic squamous cell esophageal cancer who underwent esophagectomy with extensive lymph node dissection at Akita University Hospital between 2007 and 2010, 11 patients (6.3 %) diagnosed with ARDS during the acute phase of esophagectomy were enrolled and treated with steroid pulse therapy, high-dose (15–20 mg/kg/day) administration and tapering in this retrospective study. RESULTS: Seven of the 11 patients (63.6 %) were diagnosed with CMV reactivation based on CMV antigenemia assayed 19.1 days after the start of methylprednisolone administration and were treated with ganciclovir for 39.6 days. Six of the 7 patients (85.7 %) diagnosed with CMV reactivation were administered a total methylprednisolone dose of more than 4,000 mg. Though there was no significant difference between patients with and without CMV reactivation, there was a tendency that patients with CMV reactivation showed a lower minimum number of lymphocytes during the acute phase of esophagectomy (p = 0.051, Student’s t test, average 223.3 and 298.0/μl, respectively). CONCLUSION: Though the number of study patients is small, the prevalence of CMV reactivation caused by high-dose methylprednisolone therapy for ARDS after esophagectomy is remarkably high. This result strikes a note of warning concerning the management of these patients and suggests the importance of screenings for CMV reactivation so as to make an accurate diagnosis and initiate treatment in a timely manner.
has issue date	2012-04-27(xsd:dateTime)
bibo:doi	10.1007/s10388-012-0316-x
has license	no-cc
sha1sum (hex)	6edc625743325bf825f4172dcec8f8711039d9af
schema:url	https://doi.org/10.1007/s10388-012-0316-x
resource representing a document's title	CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy
has PubMed Central identifier	PMC7101544
schema:publication	Esophagus
resource representing a document's body	covid:6edc625743325bf825f4172dcec8f8711039d9af#body_text
is schema:about of	named entity 'Method' named entity 'Conclusion' named entity 'assayed' named entity 'methylprednisolone' named entity 'thoracic' named entity 'CMV' named entity 'CMV' named entity 'ganciclovir' named entity 'therapy' named entity 'HIGH' named entity 'TREATMENT' named entity 'HIGH-DOSE' named entity 'CONSECUTIVE' covid:arg/6edc625743325bf825f4172dcec8f8711039d9af named entity 'ARDS' named entity 'esophagectomy' named entity 'Cytomegalovirus' named entity 'immunocompromised' named entity 'management' named entity 'prevalence' named entity 'diagnosis' named entity 'squamous cell' named entity 'This' named entity 'thoracic' named entity 'CMV' named entity 'ARDS' named entity 'acute phase' named entity 'acute phase' named entity 'CMV' named entity 'ganciclovir' named entity 'esophageal cancer' named entity 'methylprednisolone' named entity 'CMV' named entity 'Akita University' named entity 'CMV' named entity 'immunosuppressed' named entity 'CMV' named entity '5.0' named entity 'respiratory function' named entity 'Japan' named entity 'informed consent' named entity 'ARDS' named entity 'mechanical ventilation' named entity 'ARDS' named entity 'virus' named entity 'esophageal cancer' named entity 'significant difference' named entity 'ethics committee' named entity 'CMV infection' named entity 'oral care' named entity 'ARDS' named entity 'chemotherapy' named entity 'respiratory function' named entity 'ICU' named entity 'minimum number' named entity 'minimum number' named entity 'pneumonia' named entity 'CMV' named entity 'high-dose' named entity 'ARDS' named entity 'Acute respiratory distress syndrome' named entity 'metastasis' named entity 'CMV' named entity 'acute phase' named entity 'methylprednisolone' named entity 'CMV' named entity 'virus' named entity 'ARDS' named entity 'steroid' named entity 'lymphocytes' named entity 'septic shock' named entity 'CMV' named entity 'retinitis' named entity 'chest X-ray' named entity 'viral infection' named entity 'Esophagectomy' named entity 'CMV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software